Multiple Myeloma Clinical Trials in Portland, Oregon

11 studies are recruiting for multiple myeloma in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Oregon Health and Science University, Portland, Oregon

   Locations

   52 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06297226 on ClinicalTrials.gov

2. A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

   Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oregon Health and Science University /ID# 272282, Portland, Oregon

   Locations

   50 in total

   Run by

   AbbVie

   See if you can join NCT06953960 on ClinicalTrials.gov

3. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Providence Health & Services, Portland, Oregon

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

4. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Oregon Health And Science University, Portland, Oregon

   Locations

   144 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

5. Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

   The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressi…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Oregon Health & Science University, Portland, Oregon

   Locations

   3 in total

   Run by

   Irene Ghobrial, MD

   See if you can join NCT05469893 on ClinicalTrials.gov

6. Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

   This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patien…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Oregon Health and Science University, Portland, Oregon

   Locations

   10 in total

   Run by

   University of Alabama at Birmingham

   See if you can join NCT05231629 on ClinicalTrials.gov

7. Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

   The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland, Oregon

   Locations

   40 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT03761108 on ClinicalTrials.gov

8. Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

   The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.

   Stage

   Not phased

   Ages

   Any age

   Site

   Local Institution - 0016, Portland, Oregon

   Locations

   8 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06357754 on ClinicalTrials.gov

9. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

   This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

   Stage

   Not phased

   Ages

   40 and older

   Site

   Oregon Health Sciences University, Portland, Oregon

   Locations

   17 in total

   Run by

   Adela, Inc

   See if you can join NCT05366881 on ClinicalTrials.gov

10. Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

    This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT06784167 on ClinicalTrials.gov

11. IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

    This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and pr…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Providence Cancer Institute Franz Clinic, Portland, Oregon

    Locations

    12 in total

    Run by

    Indapta Therapeutics, INC.

    See if you can join NCT06119685 on ClinicalTrials.gov